ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

XBIT

XBiotech (XBIT)

XBiotech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XBIT
DateTimeSourceHeadlineSymbolCompany
08/02/202404:36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
08/02/202404:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
06/01/202402:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XBITXBiotech Inc
05/01/202401:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XBITXBiotech Inc
05/01/202401:00GlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
05/01/202401:00GlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
15/11/202301:00GlobeNewswire Inc.Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisNASDAQ:XBITXBiotech Inc
10/11/202306:41Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
26/09/202323:00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeNASDAQ:XBITXBiotech Inc
30/08/202323:00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic CancerNASDAQ:XBITXBiotech Inc
12/08/202301:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
09/08/202301:47GlobeNewswire Inc.XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialNASDAQ:XBITXBiotech Inc
26/06/202322:48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
26/06/202322:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
26/06/202322:43Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
26/06/202322:40Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
24/06/202305:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
20/06/202323:20Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:XBITXBiotech Inc
22/05/202323:00GlobeNewswire Inc.FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsNASDAQ:XBITXBiotech Inc
17/05/202323:22Edgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:XBITXBiotech Inc
17/05/202323:00GlobeNewswire Inc.XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesNASDAQ:XBITXBiotech Inc
11/05/202305:42Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XBITXBiotech Inc
29/04/202302:38Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:XBITXBiotech Inc
29/04/202302:33Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XBITXBiotech Inc
15/02/202322:12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
11/02/202304:22Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
11/02/202304:21Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
11/02/202304:21Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
13/01/202302:29Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XBITXBiotech Inc
10/11/202207:27Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XBITXBiotech Inc
 Showing the most relevant articles for your search:NASDAQ:XBIT
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com